Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
FDA warns that Tessalon Liquid Cough Capsules can Prove Fatal in Children
- Date: December 15, 2010
- Source: Admin
![Webinar All Access Pass Subscription](https://www.complianceonline.com/images/banners/webinar-subscription-main.png)
Tessalon (benzonatate) is an FDA-approved symptomatic cough relief drug for patients older than 10 years. However, this drug may attract younger children because of its candy-like appearance (round, liquid-filled gelatin capsule). The safety and effectiveness of benzonatate in children younger than 10 years has not been established. The FDA has therefore warned that accidental ingestion of Tessalon by children younger than 10 years can lead to serious side effects or even death.
Seven cases of accidental ingestion associated with benzonatate in children younger than 10 years were identified between 1982 and 2010. Five of the children died and they were up to two years old. Accidental ingestion of just one or two capsules leading to an overdose of benzonatate in children younger than two years of age has been reported. Amongst adverse consequences, cardiac arrest, coma, and convulsion have been reported. Signs and symptoms of overdose can occur within 15 or 20 minutes of ingestion.
The FDA is also adding a new Warning and Precaution section to the benzonatate drug label to warn health care professionals about accidental ingestion leading to overdose and death in children younger than 10.
Regulations
The Prescription Drug Marketing Act (PDMA) of 1987 is a U.S federal law. The U.S. Food & Drug Administration (FDA) issued regulations implementing the PDMA in 1990 (21 C.F.R. Part 205) and 1999 (21 C.F.R. Part 203). It establishes legal safeguards for prescription drug distribution to ensure safe and effective pharmaceuticals. It is designed to discourage the sale of counterfeit, adulterated, misbranded, sub-potent, and expired prescription drugs. The agency can seek removal of adulterated and misbranded drugs from the market and cause issue of a restraining order against the manufacturer or distributor of the drug.
Seven cases of accidental ingestion associated with benzonatate in children younger than 10 years were identified between 1982 and 2010. Five of the children died and they were up to two years old. Accidental ingestion of just one or two capsules leading to an overdose of benzonatate in children younger than two years of age has been reported. Amongst adverse consequences, cardiac arrest, coma, and convulsion have been reported. Signs and symptoms of overdose can occur within 15 or 20 minutes of ingestion.
The FDA is also adding a new Warning and Precaution section to the benzonatate drug label to warn health care professionals about accidental ingestion leading to overdose and death in children younger than 10.
Regulations
The Prescription Drug Marketing Act (PDMA) of 1987 is a U.S federal law. The U.S. Food & Drug Administration (FDA) issued regulations implementing the PDMA in 1990 (21 C.F.R. Part 205) and 1999 (21 C.F.R. Part 203). It establishes legal safeguards for prescription drug distribution to ensure safe and effective pharmaceuticals. It is designed to discourage the sale of counterfeit, adulterated, misbranded, sub-potent, and expired prescription drugs. The agency can seek removal of adulterated and misbranded drugs from the market and cause issue of a restraining order against the manufacturer or distributor of the drug.
Source:
http://en.wikipedia.org/wiki/Food_and_Drug_Administration
Compliance Trainings
![](/images/products/medium/700851.jpg)
How FDA trains its investigators to review CAPA and what should you do to prepare
By - Jeff Kasoff
On Demand Access Anytime
By - Jeff Kasoff
On Demand Access Anytime
Excel Spreadsheets; Ensuring Data Integrity and 21 CFR Part 11 Compliance
By - David Nettleton
Live September 10, 2024
By - David Nettleton
Live September 10, 2024
![](/images/products/medium/701585.jpg)
Water System Investigation "How-To's" and Example Case Studies
By - T.C Soli
On Demand Access Anytime
By - T.C Soli
On Demand Access Anytime
![](/images/products/medium/701766.jpg)
Solutions for Addressing Fungal and Bacterial Spore Outbreaks in Pharmaceutical, Biotech, and Medical Device Operations
By - Jim Polarine
On Demand Access Anytime
By - Jim Polarine
On Demand Access Anytime
Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed
![Loading](/images/attendeeimages/ajax-loader.gif)